Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46.

Article  CAS  PubMed  Google Scholar 

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020–31.

Article  CAS  PubMed  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

Article  CAS  PubMed  Google Scholar 

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68.

Article  CAS  PubMed  Google Scholar 

Verma V, Sprave T, Haque W, Simone CB, Chang JY, Welsh JW, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6:128.

Article  PubMed  PubMed Central  Google Scholar 

Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38.

Article  PubMed  PubMed Central  Google Scholar 

Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med. 1910;3:1–48.

CAS  PubMed  PubMed Central  Google Scholar 

Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, et al. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Ann Oncol. 2018;29:2163–74. In this article, an expert meeting sponsored by the European Society for Medical Oncology provide valuable definitions of terms to be used in intratumoral immunotherapy clinical trials. Important recommendations on data collection methodologies are also provided.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marabelle A, Tselikas L, de Baere T, Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol. 2017;28:xii33–43.

Article  CAS  PubMed  Google Scholar 

Kimura Y, Ghosn M, Cheema W, Adusumilli PS, Solomon SB, Srimathveeralli G. Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors. Mol Ther Oncolytics. 2022;24:194–204. In this article, authors provide an important overview of the potential role of interventional radiology in immuno-oncology, particularly regarding chimeric antigen receptor T cell therapy.

Article  PubMed  Google Scholar 

Vitale I, Shema E, Loi S, Galluzzi L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021;27:212–24.

Article  CAS  PubMed  Google Scholar 

Sun S, Hao H, Yang G, Zhang Y, Fu Y. Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies. J Immunol Res. 2018;2018:2386187.

Article  PubMed  PubMed Central  Google Scholar 

Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, Mayer AT, Gambhir SS, et al. Eradication of spontaneous malignancy by local immunotherapy. Sci Transl Med. 2018;10:eaan488.

Article  Google Scholar 

Tran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med. 2018;6:166.

Article  PubMed  PubMed Central  Google Scholar 

Shahrouki P, Lee JM, Barclay J, Khan SN, Genshaft S, Abtin F, et al. Technical feasibility and safety of repeated computed tomography-guided transthoracic intratumoral injection of gene-modified cellular immunotherapy in metastatic NSCLC. JTO Clin Res Rep. 2021;2:100242.

PubMed  PubMed Central  Google Scholar 

Sheth RA, Murthy R, Hong DS, Patel S, Overman MJ, Diab A, et al. Assessment of image-guided intratumoral delivery of immunotherapeutics in patients with cancer. JAMA Netw Open. 2020;3:e207911.

Article  PubMed  Google Scholar 

Suh RD, Goldin JG, Wallace AB, Sheehan RE, Heinze SB, Gitlitz BJ, et al. Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment. Radiology. 2004;231:359–64.

Article  PubMed  Google Scholar 

Ghosn M, Cheema W, Zhu A, Livschitz J, Maybody M, Boas FE, et al. Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial. Lung Cancer. 2022;165:1–9.

Article  CAS  PubMed  Google Scholar 

Waddill W, Wright W, Unger E, Stopeck A, Akporiaye E, Harris D, et al. Human gene therapy for melanoma: CT-guided interstitial injection. AJR Am J Roentgenol. 1997;169:63–7.

Article  PubMed  Google Scholar 

Tselikas L, Dardenne A, de Baere T, Faron M, Ammari S, Farhane S, et al. Feasibility, safety and efficacy of human intra-tumoral immuno-therapy Gustave Roussy’s initial experience with its first 100 patients. Eur J Cancer. 2022;172:1–12.

Article  PubMed  Google Scholar 

Tselikas L, Champiat S, Sheth RA, Yevich S, Ammari S, Deschamps F, et al. Interventional radiology for local immunotherapy in oncology. Clin Cancer Res. 2021;27:2698–705.

Article  PubMed  Google Scholar 

Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol. 2021;18:558–76. This article presents all currently used immunotherapy agents in intratumoral immunotherapy studies. Rationale and history of intratumoral immunotherapy are also provided.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alvarez M, Molina C, De Andrea CE, Fernandez-Sendin M, Villalba M, Gonzalez-Gomariz J, et al. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. J Immunother Cancer. 2021;9:e002953.

Article  PubMed  PubMed Central  Google Scholar 

Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375:2561–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.

Article  CAS  PubMed  Google Scholar 

Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, et al. Evaluation of HCC response to locoregional therapy: validation of MRI-based response criteria versus explant pathology. J Hepatol. 2017;67:1213–21.

Article  PubMed  Google Scholar 

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S-150S.

Article  CAS  PubMed  Google Scholar 

Hagemann AR, Cadungog M, Hagemann IS, Hammond R, Adams SF, Chu CS, et al. Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. Cancer Biol Ther. 2011;12:357–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, et al. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep. 2019;9:17589.

Article  PubMed  PubMed Central  Google Scholar 

Muñoz NM, Williams M, Dixon K, Dupuis C, McWatters A, Avritscher R, et al. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy. J Immunother Cancer. 2021;9:e001800.

Article  PubMed  PubMed Central  Google Scholar 

Midia M, Odedra D, Shuster A, Midia R, Muir J. Predictors of bleeding complications following percutaneous image-guided liver biopsy: a scoping review. Diagn Interv Radiol. 2019;25:71–80.

Article  PubMed  PubMed Central  Google Scholar 

Singh AK, Shankar S, Gervais DA, Hahn PF, Mueller PR. Image-guided percutaneous splenic interventions. Radiographics. 2012;32:523–34.

Article  PubMed  Google Scholar 

Manhire A, Charig M, Clelland C, Gleeson F, Miller R, Moss H, et al. Guidelines for radiologically guided lung biopsy. Thorax. 2003;58:920–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park B-H, Hwang T, Liu T-C, Sze DY, Kim J-S, Kwon H-C, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9:533–42.

Article  CAS  PubMed  Google Scholar 

Hamid O, Ismail R, Puzanov I. Intratumoral Immunotherapy-update 2019. Oncologist. 2020;25:e423–38.

Article  PubMed  Google Scholar 

Humeau J, Le Naour J, Galluzzi L, Kroemer G, Pol JG. Trial watch: intratumoral immunotherapy. Oncoimmunology. 2021;10:1984677.

Article  PubMed  PubMed Central  Google Scholar 

Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: first in class oncolytic virotherapy. Hum Vaccin Immunother. 2018;14:839–46.